摘要:"There has been an explosion of preclinical and clinical research leading to FDA approvals of immunotherapies that harness or enhance a patient's immune system to target tumors. However, despite promising clinical results, checkpoint blockade therapies can show intrinsic and acquired resistance and only certain tumor types respond more favorably than others. Animal models are valuable tools for studying these issues and for the preclinical evaluation of immune modulators"--
